123 related articles for article (PubMed ID: 35858589)
1. Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial.
Lan CY; Zhao J; Yang F; Xiong Y; Li R; Huang Y; Wang J; Liu C; Bi XH; Jin HH; Meng J; Zhao WH; Zhang L; Wang YF; Zheng M; Huang X
Cell Rep Med; 2022 Jul; 3(7):100689. PubMed ID: 35858589
[TBL] [Abstract][Full Text] [Related]
2. A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer.
Zhang W; Wang J; Wang Q; Cheng Y; Yang L; Li Y; Zhong H; Chu T; Dong Y; Zhang Y; Qian F; Xiong L; Shi C; Zhang C; He Z; Zhu J; Liu X; Ma H; Li K; Han B
Lung Cancer; 2023 Oct; 184():107353. PubMed ID: 37647728
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma.
Liu J; Gao T; Tan Z; Li S; Xu J; Bai C; Xue R; Xie L; Zhang L; Fan Z; Guo W
Clin Cancer Res; 2022 Aug; 28(16):3473-3479. PubMed ID: 35675031
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
Cui Q; Hu Y; Ma D; Liu H
Drug Des Devel Ther; 2021; 15():339-347. PubMed ID: 33536747
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma.
Du Y; Dai J; Mao L; Wei X; Bai X; Chen L; Lin J; Chi Z; Cui C; Sheng X; Lian B; Tang B; Wang X; Yan X; Li S; Zhou L; Guo J; Chen Y; Si L
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):93-101. PubMed ID: 37625814
[TBL] [Abstract][Full Text] [Related]
6. Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis.
Zhou J; Sun Y; Zhang W; Yuan J; Peng Z; Wang W; Gong J; Yang L; Cao Y; Zhao H; Chen C; Wang W; Shen L; Zhou A
Hepatology; 2023 Jan; 77(1):65-76. PubMed ID: 35491432
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
Xia L; Peng J; Lou G; Pan M; Zhou Q; Hu W; Shi H; Wang L; Gao Y; Zhu J; Zhang Y; Sun R; Zhou X; Wang Q; Wu X
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017154
[TBL] [Abstract][Full Text] [Related]
8. Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer.
Han Y; Wang J; Sun T; Ouyang Q; Li J; Yuan J; Xu B
Signal Transduct Target Ther; 2023 Nov; 8(1):429. PubMed ID: 37973901
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.
Xu Q; Wang J; Sun Y; Lin Y; Liu J; Zhuo Y; Huang Z; Huang S; Chen Y; Chen L; Ke M; Li L; Li Z; Pan J; Song Y; Liu R; Chen C
J Clin Oncol; 2022 Jun; 40(16):1795-1805. PubMed ID: 35192397
[TBL] [Abstract][Full Text] [Related]
10. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
[TBL] [Abstract][Full Text] [Related]
11. Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.
Lee JY; Kim BG; Kim JW; Lee JB; Park E; Joung JG; Kim S; Choi CH; Kim HS;
J Gynecol Oncol; 2022 Jul; 33(4):e45. PubMed ID: 35320892
[TBL] [Abstract][Full Text] [Related]
12. A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer.
Wang J; Sun T; Ouyang Q; Han Y; Xu B
iScience; 2023 Jun; 26(6):106876. PubMed ID: 37275528
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study.
Shen W; Jing C; Tian W; Zhang W; Ren Y; Shan B; Wang H
Int J Gynecol Cancer; 2023 Nov; 33(11):1764-1770. PubMed ID: 37775281
[TBL] [Abstract][Full Text] [Related]
14. Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study.
Moroney JW; Powderly J; Lieu CH; Bendell JC; Eckhardt SG; Chang CW; Molinero L; Spahn J; Williams P; Lin YG; Hodi FS
Clin Cancer Res; 2020 Nov; 26(21):5631-5637. PubMed ID: 32723836
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
Liu JF; Herold C; Gray KP; Penson RT; Horowitz N; Konstantinopoulos PA; Castro CM; Hill SJ; Curtis J; Luo W; Matulonis UA; Cannistra SA; Dizon DS
JAMA Oncol; 2019 Dec; 5(12):1731-1738. PubMed ID: 31600397
[TBL] [Abstract][Full Text] [Related]
16. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
[TBL] [Abstract][Full Text] [Related]
19. Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design.
Pujade-Lauraine E; Fujiwara K; Dychter SS; Devgan G; Monk BJ
Future Oncol; 2018 Sep; 14(21):2103-2113. PubMed ID: 29584456
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
